These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15784157)

  • 41. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
    Advokat C; Dixon D; Schneider J; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.
    Srisurapanont M; Maneeton N
    J Med Assoc Thai; 1999 Apr; 82(4):341-6. PubMed ID: 10410494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current pharmacotherapy of schizophrenia].
    Bitter I
    Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.
    Purdon SE; Malla A; Labelle A; Lit W
    J Psychiatry Neurosci; 2001 Mar; 26(2):137-49. PubMed ID: 11291531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
    Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
    Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clozapine: a comparison with other novel antipsychotics.
    Fleischhacker WW
    J Clin Psychiatry; 1999; 60 Suppl 12():30-4. PubMed ID: 10372608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
    Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
    Psychiatry Res; 2006 Nov; 144(2-3):177-89. PubMed ID: 17010448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.
    Stahl SM
    J Clin Psychiatry; 1999; 60 Suppl 10():31-41. PubMed ID: 10340685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
    Hermes E; Rosenheck R
    J Psychopharmacol; 2012 Sep; 26(9):1194-200. PubMed ID: 22516668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognitive improvement in schizophrenia with novel antipsychotic medications.
    Purdon SE
    Schizophr Res; 1999 Mar; 35 Suppl():S51-60. PubMed ID: 10190225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
    Kucharska-Pietura K; Tylec A; Czernikiewicz A; Mortimer A
    Med Sci Monit; 2012 Jan; 18(1):CR44-49. PubMed ID: 22207119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.